Clinical Efficacy of ABX203 Therapeutic Vaccine in HBeAg Negative Patients With Chronic Hepatitis B
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The study is an open-label, randomized, comparative, multicenter clinical trial. The purpose
of this study is to assess the efficacy of ABX203, a new chronic hepatitis B therapeutic
vaccine administered as an adjunct therapy to nucleos(t)ide analogs (NUCs), in maintaining
control of Hepatitis B disease after cessation of treatment with NUCs in subjects with HBeAg
negative chronic Hepatitis B.